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later elaborated by Knudson. The supposed monoclonal 
origin and time scale of development of papillomas are 
entirely consistent with current views.
Unfortunately, we do not know why this research was not 
continued. The war or some other misfortune may have 
prevented it, but that work3 being 30 years ahead of the 
papers usually cited, shows great imagination.
*Volker Wunderlich, Manfred F Rajewsky
*Humboldt-Unlversity and Max-Delbriick-Centre for Molecular Medicine,
D-13122 Berlin, Germany; and Institute of Cell Biology (Cancer Research),
University of Essen Medical School
1 Harris H, Miler OJ3 Klein G, Worst P> Tachibana T. Suppression of 
malignancy by cell fusion. Nature 1969; 223: 363-68.
2 Charles DR} Lu ce-Clausen EM. The kinetics of papilloma formation 
in bcnzpyrene-trcatcd mice. Cancer Res 1942; 2: 261-63.
Treatment for glioma
Sir—If a new treatment for recurrent glioma, however 
ingenious, is followed by a median survival of only 31 weeks, 
compared with 23 weeks in controls, should this really be 
described as “an effective treatment” in the way that Brem 
and colleagues (April 22, p 1008) do in their abstract? 
Having told us that those treated in this way live a few weeks 
longer than untreated controls, why do they not just leave it 
at that? Readers can then decide for themselves whether to 
call this an effective treatment—or a treatment that is having 
very little effect.
Thurstan B Brewin
18 Braybank, Bray-on-Thames, Berkshire SL6 2BQ, UK
Glutathione S-transferase alpha as marker for 
hepatocellular damage in pre-eclampsia and 
HELLP syndrome
Sir—Pre-eclampsia and the syndrome of haemolysis, 
elevated liver enzymes, and low platelets (HELLP) represent 
major causes of maternal and perinatal morbidity and 
mortality. Correct assessment of hepatocellular damage is 
crucial in the clinical management of these patients. 
Glutathione S-transferase alpha (GSTa) is a cytosolic 
enzyme found in high concentrations in the liver (3 mg/g wet 
weight) with a short plasma half-life of 2 h. Since no clinical 
conditions other than hepatic diseases are known to cause 
raised plasma concentrations of GSTa, plasma 
measurements of this enzyme may therefore provide a fast, 
specific, and sensitive index of acute hepatocellular damage.1 
We studied plasma concentrations of GSTa and alanine 
aminotransferase (ALT) in 21 patients with pre-eclampsia 
(phase IV diastolic blood pressure >100 mm Hg and 
proteinuria >500 mg per 24 h, median 30 and range 26-39 
weeks’ gestation), 8 of whom had developed HELLP 
syndrome according to die criteria of Sibai.2
Plasma GST« concentrations were measured with a 
sandwich ELISA. The assay uses an anti-human GSTa 
mouse monoclonal as catching antibody and rabbit anti­
human GSTa antiserum, both developed in our laboratory, 
as the source of the detecting antibodies.3 The assay has no 
cross-reactivity with other human GSTs and the variations 
within and between assays are 2*5% and 7*3%, respectively. 
An upper normal reference value of 10*0 ng/mL was 
calculated by use of plasma samples from 225 healthy blood 
donors. In 71 women during the third trimester of 
uncomplicated pregnancy, plasma GSTa values were always 
below 10-0 ng/mL. The upper limit of the reference range
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Figure: Plasma concentrations of GSTa and ALT expressed as 
multiples of upper normal reference value in 2 patients (A and 
B) with HELLP syndrome
for ALT in our hospital is 30 IU/L. 16 women had raised 
ALT values (median 4*2 times upper normal reference 
value, range 1*5-35-7). In all these patients GSTa values 
were also raised (median 37*0 times the upper normal 
reference value, range 1 *9—1148*0). However, the relative 
magnitude of abnormality of GSTot was remarkably greater 
(almost 10 times) than that of ALT.
In addition 2 nulliparous women (A and B) who 
developed HELLP syndrome were studied prospectively 
after admission at 26 and 28 weeks’ gestation (figure). Both 
women had substantial rises in plasma GSTa during 
recurrent periods of severe epigastric pain. The rises 
preceded those of ALT by several hours and the relative 
magnitude of the abnormality of GSTa at peak 
concentrations was between 10 and 100 times greater than 
for the aminotransferase. When the upper abdominal pain 
subsided, plasma GSTa declined more quickly than ALT. 
Both patients underwent emergency caesarean section 
during the second (A) or third (B) attack of epigastric pain 
with subsequent uneventful recovery. Both babies required 
assisted ventilation but are now developing normally.
Measurement of plasma GSTa might provide an earlier 
and much more sensitive indicator of acute hepatocellular 
damage, as well as of its resolution, in pre-eclampsia and the 
HELLP syndrome than the aminotransferases. Better
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assessment of severity of hepatic involvement is likely to 
improve clinical management, and the timing of delivery in 
particular, of these high-risk obstetric patients.
*E A P Steegers, T P J Mulder, J G A Bisseling,
F M C Delemarre, W H M Peters
Departments of *Obstetrics/Gynaecology and Gastroenterology/Hepatology, 
University Hospital St Radboud, PO Box 9101, 6500 HB Nijmegen, Netherlands
1 Beckett GJ, Hayes JD. Glutathione S-transferases: biochemical 
applications. Adv Clin Chcm 1993; 30: 281-380.
2 Sibai BM. The HELLP syndrome (hemolysis, elevated liver enzymes, 
and low platelets): much ado about nothing? Am J  Obstet Gynecol 
1990; 162:311-16.
3 Nijhoff WAj Mulder TPJ, Verhagen H, van Poppel G, Peters WHM. 
Effects of consumption of Brussels sprouts on plasma and urinary 
glutathione S-transferase class-a and -tt in humans. Carcinogenesis 
1995; 16: 955-57.
Thyrotropin-releasing hormone for prevention 
of neonatal respiratory disease
Sir—The ACTOBAT group report (April 8, p 877) the 
results of their trial of thyrotropin-releasing hormone (TRH) 
for prevention of respiratory disease in premature infants. 
Their findings seem to differ from previously published 
findings, including our trial.1 The ACTOBAT trial is an 
important contribution in view of the large sample size and 
analysis by intention-to-treat. With respect to the failure to 
demonstrate efficacy, it should be noted that although not 
statistically significant* there was a trend in the ACTOBAT 
trial toward fewer deaths or lower oxygen requirement at 28 
days and less severe respiratory distress syndrome (RDS) 
among TRH-treated infants delivering less than 10 days 
after entry into the trial. These are the infants at highest risk, 
and results for this group are similar to our data and that of 
Knight et al.2 However, the magnitude of the response is less 
than seen in the previous studies3 which is indeed puzzling.
The ACTOBAT investigators discuss the lower dose of 
TRH used (200 vs 400 jig) but do not comment on the less 
frequent administration (every 12 h vs 8 h) than in other 
trials. Their treatment regimen possibly did not sustain 
raised hormone concentrations in the fetuses. The increase 
in fetal TSH and thyroid hormones is transient and values 
fall to below control values by 7-12 h after infusion of 
TRH.3 Unfortunately3 the ACTOBAT study does not 
provide data for thyroid hormones in cord blood of infants 
to address this possibility.
Other possibilities for the reduced efficacy in die 
ACTOBAT trial might relate to the use of steroids and 
replacement surfactant. Women in the trial rarely received 
retreatment witii antenatal steroids for recurrent premature 
labour3 a practice that was common in other studies. 
Steroids are also routinely used postnatally to treat 
established lung disease3 and this potential confounder was 
not addressed in the ACTOBAT report. Surfactant 
treatment was introduced in Australia during the period of 
patient enrolment. Apparently there was no uniform 
guidelines for this treatment nor was analysis done with this 
. important variable as a covariate.
The second major conclusion related to perinatal and 
maternal risk. It should be noted that the two adverse 
responses of TRH on neonatal outcome3 any RDS and need 
for ventilation* were both of marginal significance with 
confidence intervals at 1-0. Most importantly, there was no 
excess of severe RDS in the TRH group and the duration of 
ventilation was not different for the two groups. Thus3 it is 
uncertain whether these observations are clinically 
important.
The maternal findings of nausea and vomiting are known
and transient side-effects of TRH treatment in adults and 
have been recorded in other prenatal trials, although at lower 
frequency.1,2 The blood pressure increase is potentially of 
concern, especially in women with pre-eclampsia;4 however, 
there have been no reports of clinical problems related to the 
transient increase. By contrast with the ACTOBAT results 
we did not find a significant increase in maternal blood 
pressure, defined as an increase greater than 20 mm Hg, 
with a lower level of existing maternal hypertension as an 
exclusion criterion.1
We are undertaking a large US collaborative trial of 
antenatal TRH with our previous treatment protocol, plus 
routine postnatal surfactant as clinically indicated, and we 
will analyse by intention-to-treat, as for the ACTOBAT trial. 
We are doing serial measurements of thyroid hormones and 
a TRH stimulation test to investigate suppression and 
responsiveness of the thyroid axis. Our results together with 
those of the planned European trial should elucidate the 
risks and benefits of this treatment. In the meantime we 
agree with the conclusion of the ACTOBAT investigators 
that antenatal TRH cannot be recommended for routine 
clinical use at present.
*  Roberta A Ballard, Philip L Ballard, Avital Cnaan,
Jennifer Pinto-Martin
Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA
1 Ballard RA, Ballard PL, Creasy RK, et al. Respiratory disease in very- 
low-birthweight infants after prenatal thyrotropin-releasing hormone 
and glucocorticoid. Lancet 1992; 339: 510-15.
2 Knight DB, Liggins GC3 Wealthall SR. A randomised controlled trial 
of antepartum thyrotropin-releasing hormone and betamethasone in 
the prevention of respiratory disease in preterm infants. A m  J  Obstet 
Gynecol 1994; 171: 11-16.
3 Ballard RA, Ballard PL, Creasy RK} et al. Plasma thyroid hormones 
and prolactin in premature infants and their mothers after prenatal 
treatment with thyrotropin-releasing hormone. Pediatr Res 1992; 32: 
673-78.
4 Peek MJ3 Baloria Rs Shennan AH, et al. Hypertensive effect of 
antenatal thyrotropin-releasing hormone in pre-eclampsia. Lancet 
1995; 345:793.
S ir—The ACTOBAT group study of antenatal TRH for 
prevention of neonatal respiratory disease used a lower dose 
(200 pig) than that administered in previous trials. In fetal 
sheep, glucocorticoids alone can enhance lung maturation, 
but a better effect than that of glucocorticoids is observed 
only with a combination of glucocorticoids, triiodothyronine, 
and prolactin.1 Thus the efficacy of TRH may depend on its 
ability to maintain raised fetal concentrations of 
triiodothyronine and prolactin. Furthermore, fetal TRH 
concentrations themselves may be important if part of the 
beneficial effects of this hormone are mediated through its 
direct neurotransmitter action. We have shown that 400 fig 
TRH can increase both triiodothyronine and prolactin in 
preterm human fetuses.2 However, this effect lasts only 
6-8 h—hence the recommendation to use 400 fig every 8 h 
in antenatal efforts to mature the fetal lung. A lower dose, 
such as that used in ACTOBAT, does not stimulate 
prolactin release in the preterm human fetus.3 Our 
preliminary findings on the dose-response to TRH in 
preterm human fetuses also suggest that, whereas maternal 
administration of 200 jxg may result in increases of fetal 
triiodothyronine which -are comparable with those observed 
after 400 (JLg, the increase in the pituitary hormones 
thyrotropin and prolactin are lower.1 Although we do not 
know how far the concentrations of fetal TRH are modified 
by maternal administration of this hormone, lower doses of 
TRH probably result in lower fetal levels as well. Thus it is 
quite likely that ACTOBAT used less TRH than is 
necessary to provide optimum increases of fetal hormones to 
mature the fetal lung.
1572 Voi 345 - June 17, 1995
